# ITU Tier 1 Paper #26 — Immunology (Block B Opener)

Information-Theoretic Unification (ITU) Framework — Tier 1 paper #26, opening **Block B (Life Sciences Deepening)**. Introduces K_immune across 8 sub-states.

- **Author**: Munehiro Terada (Roboken) — munehiro.terada@roboken2.com
- **Concept DOI (ITU)**: [10.5281/zenodo.20109209](https://doi.org/10.5281/zenodo.20109209)
- **Tier 0 v3.0**: [10.5281/zenodo.20200156](https://doi.org/10.5281/zenodo.20200156)
- **This paper DOI**: 10.5281/zenodo.20256116
- **Version**: 1.0.0 / **Date**: 2026-05-17 / **License**: CC-BY-4.0

## K_immune structure (8 sub-states)

```
K_immune = K_innate ⊕ K_adaptive ⊕ K_MHC ⊕ K_affinity
         ⊕ K_tolerance ⊕ K_vaccine ⊕ K_tumor ⊕ K_infect
```

## Phase 183-190 Summary

| Phase | Topic | Headline |
|---|---|---|
| 183 | Innate + Adaptive + K_immune intro | V(D)J 10¹⁸, R₀ verification |
| 184 | TCR/BCR + V(D)J recombination | repertoire 5.8e13 / 2.0e18, ITU 1.000 |
| 185 | MHC + Antigen Presentation | HLA 35,800 alleles; B27/AS OR=87 |
| 186 | Affinity Maturation + Germinal Center | Kd 317×, ITU 1.000 × 8 cycles |
| 187 | Tolerance + Autoimmunity | AIRE/Treg; SLE F:M=9:1 |
| 188 | Vaccines + mRNA + Prime-Boost | BNT 95%; Karikó-Weissman Nobel 2023 |
| 189 | Tumor Immunology + Checkpoint + CAR-T | Allison-Honjo Nobel 2018; Tisa 83% CR |
| 190 | Integration + 26-vertex polytope | P_avg=0.620, Pass-1 86.4% |

## ITU axiom δS/δ⟨K⟩ = 1 verified in 7+ contexts

| Phase | Context | Ratio |
|---|---|---|
| 184 | Repertoire evolution | 1.000000 |
| 185 | MHC negative selection | 1.000000 |
| 186 | Germinal center × 8 cycles | 1.000000 |
| 188 | Prime → Boost | 1.000000 |
| 188 | Boost → Memory | 1.000000 |
| 189 | Checkpoint inhibitor | 1.000000 |
| 189 | CAR-T | 0.999999 |

## 26-Vertex Polytope

| Indicator | Value |
|---|---|
| Vertices | 26 |
| Edges | 196 |
| Mean degree | 15.08 |
| **#26 Immune degree** | **25 (new max)** |

## 10 Falsifiable Predictions (P_avg = 0.620)

Pan-coronavirus mRNA vaccine 2028 (P=0.70), cancer neoantigen mRNA 2028 (P=0.75), saRNA single-dose 2027 (P=0.80), in vivo CAR-T 2028 (P=0.75), CAR-NK allogeneic 2027 (P=0.70), pan-cancer PD-1 biomarker 2028 (P=0.60), universal autoimmune biomarker 2032 (P=0.45), ITU TMB threshold 2030 (P=0.50), HIV mRNA >70% 2030 (P=0.40), universal flu Phase III 2030 (P=0.55).

**Strong/Medium/Weak = 5/4/1**

## Files

### Theory (Phase 183-190)
`theory_phase183.md` … `theory_phase190.md`

### Simulations (.py + .png + _summary.json)
- `innate_adaptive_immunity` — Phase 183
- `vdj_repertoire` — Phase 184
- `mhc_antigen_presentation` — Phase 185
- `affinity_maturation_gc` — Phase 186
- `tolerance_autoimmunity` — Phase 187
- `vaccine_mrna_prime_boost` — Phase 188
- `tumor_immunology_cart` — Phase 189
- `polytope_26vertex_immune` — Phase 190

### Paper (consolidated)
- `paper_tier1_26_immunology.md`

## Pass-1 progress

- ✅ Phase 1-182: Block A 9/9 COMPLETE
- ✅ **Phase 183-190: #26 Immune (this paper) ← 86.4% ★**
- ⏳ Phase 191-219: Tier 1 #27-#45

## License

CC-BY-4.0 — https://creativecommons.org/licenses/by/4.0/
